16:32 , Jun 20, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Viral infection; polio Cell culture studies identified benzothiophene-based VP1 inhibitors that could help treat human rhinovirus (HRV) or poliovirus infections. Screening of a small molecule library, chemical synthesis of analogs of the screening hit,...
02:13 , Feb 23, 2017 |  BC Week In Review  |  Clinical News

Vapendavir: Ph IIb SPIRITUS data

Top-line data from the double-blind, international Phase IIb SPIRITUS trial in 168 evaluable patients ages 18-70 with moderate to severe asthma and laboratory-confirmed HRV infection showed that twice-daily 264 and 528 mg doses of oral...
01:26 , Jan 6, 2017 |  BC Innovations  |  Product R&D

Viral ambitions

  Meissa Vaccines Inc. is translating studies from an Emory University team into a pair of vaccine platforms to protect specific at-risk subpopulations from infections by two otherwise innocuous viruses, RSV and the common cold....
23:11 , Nov 2, 2016 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Viral infection Non-human primate studies suggest a polyvalent inactivated human rhinovirus (HRV) vaccine could help prevent HRV infection. The vaccine consisted of 50 formalin-inactivated HRV strains expressing a range of differing HRV capsids, plus...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Clinical News

Vapendavir: Phase IIb started

Biota began the double-blind, placebo-controlled, dose-ranging, international Phase IIb SPIRITUS trial to evaluate 264 and 528 mg oral vapendavir twice daily for 7 days in about 150 patients with moderate to severe asthma and HRV...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Clinical News

Vapendavir: Development halted

Biota disclosed in its fiscal 4Q13 earnings ending June 30 that it will not independently develop vapendavir to treat HRV infection in patients with moderate to severe asthma or chronic obstructive pulmonary disease (COPD). The...
07:00 , Apr 2, 2012 |  BC Week In Review  |  Clinical News

Vapendavir: Phase II data

A double-blind, U.S. Phase II trial in 300 asthmatic adults with symptomatic, naturally acquired HRV infection showed that twice-daily 400 mg oral vapendavir for 6 days met the primary endpoint of reducing the severity of...
07:00 , Aug 2, 2010 |  BC Week In Review  |  Clinical News

BTA798: Phase II started

Biota began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate oral BTA798 in up to 400 patients with chronic asthma. Biota Holdings Ltd. (ASX:BTA), Notting Hill, Australia   Product: BTA798   Business: Infectious  ...